<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00880230</url>
  </required_header>
  <id_info>
    <org_study_id>P-999</org_study_id>
    <nct_id>NCT00880230</nct_id>
  </id_info>
  <brief_title>Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent (INTENSE)</brief_title>
  <acronym>INTENSE</acronym>
  <official_title>INTENSE: Iliac Artery Treatment With The Invatec Scuba™ Cobalt Chromium Stent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of the Scuba™ stent in
      subjects with symptomatic claudication or rest pain and angiographic confirmation of de novo
      or restenotic lesions in the common and/or external iliac artery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interventional revascularization strategies for peripheral arterial disease currently
      available include both surgical and endovascular approaches such as percutaneous transluminal
      angioplasty (PTA), either as a stand-alone procedure or with the placement of a stent.
      Cobalt-chromium (CoCr) is an alloy that has been used safely in the manufacture of surgical
      implants for use in contact with blood, soft tissue and bone for over 10 years. This study
      will evaluate the SCUBA™ peripheral balloon-expandable cobalt chromium tent system in iliac
      arteries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or Death Within 9 Months Post-procedure.</measure>
    <time_frame>In-hospital and 9 Months</time_frame>
    <description>The analysis is based on the percentage of Intent to Treat subjects (ITT) who experienced the primary endpoint or who had adequate follow-up for the 9-month analysis. A subject had adequate follow-up if he/she had an event or had a follow-up of at least 256 days, allowing for a visit window of 9 months +/- 14 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Vascular Events Through 30 Days as a Composite of (MI, Death or Stroke, Stent Thrombosis, Distal Embolization, Arterial Rupture/Perforation, Acute Limb Ischemia, Target Limb Loss, Procedure-related Bleeding Event Requiring Transfusion)</measure>
    <time_frame>30 Days</time_frame>
    <description>The analysis is based on the number of patients who experienced either an MI, died, had a stroke, stent thrombosis, distal embolization, arterial rupture/perforation limb ischemia, lost a target limb, or had a bleeding event due to the procedure within 30 days after being treated with the Scuba iliac stent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>At time of deployment</time_frame>
    <description>The outcome is based on the successful delivery and deployment of the Scuba iliac stent and the intact retrieval of the delivery system.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Up to the moment the catheter sheath introducer has been removed</time_frame>
    <description>The outcome is based on the successful delivery and deployment of the Scuba iliac stent and the intact retrieval of the delivery system [Device Success] and the achievement of &lt;30% residual stenosis immediately after stent deployment, without occurrence of in-hospital Major Adverse Events (MAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Early Clinical Success (30 days) is defined as improvement of the Rutherford-Becker scale criteria by greater than or equal to one category as obtained at the 30 day follow-up visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>6 Months</time_frame>
    <description>Late Clinical Success (6 months) is defined as a maintained improvement in Ankle-Brachial Index (ABI) or Thigh-Brachial Index (TBI) assessed as either a) normalized (0.90) or b) an increase by 0.1 from the baseline level and had not decreased by more than 0.15 from the maximum result observed immediately post-procedure. In the absence of ABI/TBI data, Late Clinical Success was assessed in the same manner as Early Clinical Success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Success</measure>
    <time_frame>9 Months</time_frame>
    <description>Late Clinical Success (9 months) is defined as a maintained improvement in Ankle-Brachial Index (ABI) or Thigh-Brachial Index (TBI) assessed as either a) normalized (0.90) or b) an increase by 0.1 from the baseline level and had not decreased by more than 0.15 from the maximum result observed immediately post-procedure. In the absence of ABI/TBI data, Late Clinical Success was assessed in the same manner as Early Clinical Success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency - Primary</measure>
    <time_frame>6 Months</time_frame>
    <description>Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency - Primary Assisted</measure>
    <time_frame>6 Months</time_frame>
    <description>Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (0-99%) at any time post-procedure through 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency - Secondary</measure>
    <time_frame>6 Months</time_frame>
    <description>Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at post-procedure through 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency - Primary</measure>
    <time_frame>9 Months</time_frame>
    <description>Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency - Primary Assisted</measure>
    <time_frame>9 Months</time_frame>
    <description>Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (0-99%) at any time post-procedure through 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patency - Secondary</measure>
    <time_frame>9 Months</time_frame>
    <description>Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at post-procedure through 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Limb Revascularization</measure>
    <time_frame>9 Months</time_frame>
    <description>Restenosis is defined as a 50% or greater diameter stenosis observed post-procedure through the 9 month timepoint. Restenosis is initially assessed by Duplex Ultrasound of the iliac artery with the common femoral artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis Rate (≥ 50% Diameter Stenosis by Duplex Ultrasound Determination)</measure>
    <time_frame>9 Months</time_frame>
    <description>Restenosis is defined as a 50% or greater diameter stenosis observed post-procedure through the 9 month timepoint. Restenosis is initially assessed by Duplex Ultrasound of the iliac artery with the common femoral artery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>9 Months</time_frame>
    <description>Death can be classified as one of three categories: cardiac, vascular, or non-cardiovascular. All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Limb Loss</measure>
    <time_frame>9 Months</time_frame>
    <description>Amputation of the target limb by surgical removal of tissue anywhere from the toe to hip in the ipsilateral limb of the target segment. Amputations are subclassified as: Above the knee, Below the knee, Transmetatarsal, and Toe.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Peripheral Artery Disease</condition>
  <arm_group>
    <arm_group_label>Scuba Iliac Stent System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Scuba™ iliac stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Scuba Iliac Stent System</intervention_name>
    <description>The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
    <arm_group_label>Scuba Iliac Stent System</arm_group_label>
    <other_name>Scuba</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Presence of de novo or restenotic lesion(s), located in the common or external iliac
             artery with ≥50% stenosis

          -  Subject has lifestyle limiting claudication or rest pain, (Rutherford- Becker scale
             [clinical category] 2, 3, or 4)

          -  Target vessel reference diameter is 5mm - 10mm by visual assessment

          -  Target lesion length &lt; 130mm

          -  Subject has angiographic evidence of a patent femoral outflow artery in the target
             limb

          -  Subject has provided written informed consent

          -  Subject is able and willing to adhere to required follow-up visits and testing

        Exclusion Criteria:

          -  Subject has lesions in the Common Femoral Artery (CFA), Profundal Femoral Artery
             (PFA), or Superficial Femoral Artery (SFA) that would require a staged procedure
             within 30 days of the index procedure (either before or after)

          -  Target lesion(s) has adjacent, acute thrombus

          -  Target lesion(s) is highly calcified or was previously treated with a stent

          -  Subject has a pre-existing target iliac artery aneurysm or perforation or dissection
             of the target iliac artery

          -  Subject has an abdominal aortic aneurysm contiguous with the iliac artery target
             lesion

          -  Subject has a post-surgical stenosis and anastomotic suture treatments in the native
             iliac vessel

          -  Subject has a vascular graft previously implanted in the native iliac vessel

          -  Subject has tissue loss - Rutherford-Becker clinical category 5 or 6

          -  History of neutropenia (WBC &lt;3,000/mm3), coagulopathy, or thrombocytopenia (platelet
             count &lt;80,000/uL)

          -  International Normalized ratio (INR) greater than 1.5

          -  Serum creatinine greater than 2.5 mg/dL

          -  Subject has a known bleeding or hypercoagulability disorder or significant anemia (Hb
             &lt; 8.0 g/dL) that cannot be corrected

          -  Subject is participating in an investigational study of a new drug, biologic, or
             device at the same time of study screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce H Gray, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Greeville Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry T Katzen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baptist Health South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baptist Hospital of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamburg University Cardiovascular Center</name>
      <address>
        <city>Hamburg</city>
        <zip>22527</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 10, 2009</study_first_submitted>
  <study_first_submitted_qc>April 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2009</study_first_posted>
  <results_first_submitted>February 1, 2013</results_first_submitted>
  <results_first_submitted_qc>May 2, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2013</results_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Iliac Artery Stenting</keyword>
  <keyword>Peripheral Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chromium</mesh_term>
    <mesh_term>Cobalt</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment was for a period of 16 months. Subjects were recruited at medical clinics who participate in clinical trials.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Scuba Iliac Stent System</title>
          <description>Device: Scuba Iliac Stent
Scuba Iliac Stent System: The Scuba Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Scuba Iliac Stent System</title>
          <description>Device: Scuba™ Iliac stent
Scuba Iliac Stent System: The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="141"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.90" spread="9.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or Death Within 9 Months Post-procedure.</title>
        <description>The analysis is based on the percentage of Intent to Treat subjects (ITT) who experienced the primary endpoint or who had adequate follow-up for the 9-month analysis. A subject had adequate follow-up if he/she had an event or had a follow-up of at least 256 days, allowing for a visit window of 9 months +/- 14 days.</description>
        <time_frame>In-hospital and 9 Months</time_frame>
        <population>Intent to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Major Adverse Events (MAE) Defined as the Occurrence of In-hospital Myocardial Infarction (MI) or Target Segment Revascularization, Target Limb Loss, or Death Within 9 Months Post-procedure.</title>
          <description>The analysis is based on the percentage of Intent to Treat subjects (ITT) who experienced the primary endpoint or who had adequate follow-up for the 9-month analysis. A subject had adequate follow-up if he/she had an event or had a follow-up of at least 256 days, allowing for a visit window of 9 months +/- 14 days.</description>
          <population>Intent to Treat Population (ITT)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" lower_limit="2.1" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Major Adverse Vascular Events Through 30 Days as a Composite of (MI, Death or Stroke, Stent Thrombosis, Distal Embolization, Arterial Rupture/Perforation, Acute Limb Ischemia, Target Limb Loss, Procedure-related Bleeding Event Requiring Transfusion)</title>
        <description>The analysis is based on the number of patients who experienced either an MI, died, had a stroke, stent thrombosis, distal embolization, arterial rupture/perforation limb ischemia, lost a target limb, or had a bleeding event due to the procedure within 30 days after being treated with the Scuba iliac stent.</description>
        <time_frame>30 Days</time_frame>
        <population>Intent to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Adverse Vascular Events Through 30 Days as a Composite of (MI, Death or Stroke, Stent Thrombosis, Distal Embolization, Arterial Rupture/Perforation, Acute Limb Ischemia, Target Limb Loss, Procedure-related Bleeding Event Requiring Transfusion)</title>
          <description>The analysis is based on the number of patients who experienced either an MI, died, had a stroke, stent thrombosis, distal embolization, arterial rupture/perforation limb ischemia, lost a target limb, or had a bleeding event due to the procedure within 30 days after being treated with the Scuba iliac stent.</description>
          <population>Intent to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" lower_limit="0.5" upper_limit="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>The outcome is based on the successful delivery and deployment of the Scuba iliac stent and the intact retrieval of the delivery system.</description>
        <time_frame>At time of deployment</time_frame>
        <population>Intent to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>The outcome is based on the successful delivery and deployment of the Scuba iliac stent and the intact retrieval of the delivery system.</description>
          <population>Intent to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95" lower_limit="90" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedural Success</title>
        <description>The outcome is based on the successful delivery and deployment of the Scuba iliac stent and the intact retrieval of the delivery system [Device Success] and the achievement of &lt;30% residual stenosis immediately after stent deployment, without occurrence of in-hospital Major Adverse Events (MAE).</description>
        <time_frame>Up to the moment the catheter sheath introducer has been removed</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Procedural Success</title>
          <description>The outcome is based on the successful delivery and deployment of the Scuba iliac stent and the intact retrieval of the delivery system [Device Success] and the achievement of &lt;30% residual stenosis immediately after stent deployment, without occurrence of in-hospital Major Adverse Events (MAE).</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.5" lower_limit="79.8" upper_limit="91.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>Early Clinical Success (30 days) is defined as improvement of the Rutherford-Becker scale criteria by greater than or equal to one category as obtained at the 30 day follow-up visit.</description>
        <time_frame>30 Days</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Early Clinical Success (30 days) is defined as improvement of the Rutherford-Becker scale criteria by greater than or equal to one category as obtained at the 30 day follow-up visit.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.8" lower_limit="88.2" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>Late Clinical Success (6 months) is defined as a maintained improvement in Ankle-Brachial Index (ABI) or Thigh-Brachial Index (TBI) assessed as either a) normalized (0.90) or b) an increase by 0.1 from the baseline level and had not decreased by more than 0.15 from the maximum result observed immediately post-procedure. In the absence of ABI/TBI data, Late Clinical Success was assessed in the same manner as Early Clinical Success.</description>
        <time_frame>6 Months</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Late Clinical Success (6 months) is defined as a maintained improvement in Ankle-Brachial Index (ABI) or Thigh-Brachial Index (TBI) assessed as either a) normalized (0.90) or b) an increase by 0.1 from the baseline level and had not decreased by more than 0.15 from the maximum result observed immediately post-procedure. In the absence of ABI/TBI data, Late Clinical Success was assessed in the same manner as Early Clinical Success.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.3" lower_limit="60" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Success</title>
        <description>Late Clinical Success (9 months) is defined as a maintained improvement in Ankle-Brachial Index (ABI) or Thigh-Brachial Index (TBI) assessed as either a) normalized (0.90) or b) an increase by 0.1 from the baseline level and had not decreased by more than 0.15 from the maximum result observed immediately post-procedure. In the absence of ABI/TBI data, Late Clinical Success was assessed in the same manner as Early Clinical Success.</description>
        <time_frame>9 Months</time_frame>
        <population>Intent to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Success</title>
          <description>Late Clinical Success (9 months) is defined as a maintained improvement in Ankle-Brachial Index (ABI) or Thigh-Brachial Index (TBI) assessed as either a) normalized (0.90) or b) an increase by 0.1 from the baseline level and had not decreased by more than 0.15 from the maximum result observed immediately post-procedure. In the absence of ABI/TBI data, Late Clinical Success was assessed in the same manner as Early Clinical Success.</description>
          <population>Intent to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" lower_limit="57.2" upper_limit="74.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency - Primary</title>
        <description>Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation at 6 months.</description>
        <time_frame>6 Months</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Patency - Primary</title>
          <description>Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation at 6 months.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.9" lower_limit="89.7" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency - Primary Assisted</title>
        <description>Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (0-99%) at any time post-procedure through 6 months.</description>
        <time_frame>6 Months</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Patency - Primary Assisted</title>
          <description>Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (0-99%) at any time post-procedure through 6 months.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.2" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency - Secondary</title>
        <description>Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at post-procedure through 6 months.</description>
        <time_frame>6 Months</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Patency - Secondary</title>
          <description>Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at post-procedure through 6 months.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="1.2" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency - Primary</title>
        <description>Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Patency - Primary</title>
          <description>Patients were assumed primary patent if the target vessel had continuous flow without revascularization, bypass, or amputation at 9 months.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.3" lower_limit="89.3" upper_limit="98.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency - Primary Assisted</title>
        <description>Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (0-99%) at any time post-procedure through 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Intention to Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Patency - Primary Assisted</title>
          <description>Primary assisted patency is defined as continuous flow assisted with a revascularization when the target vessel has restenosed (0-99%) at any time post-procedure through 9 months.</description>
          <population>Intention to Treat (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patency - Secondary</title>
        <description>Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at post-procedure through 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Patency - Secondary</title>
          <description>Secondary patency is defined as reestablishment of flow to distal arteries after 100% occlusion has occurred at the target vessel at post-procedure through 9 months.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Limb Revascularization</title>
        <description>Restenosis is defined as a 50% or greater diameter stenosis observed post-procedure through the 9 month timepoint. Restenosis is initially assessed by Duplex Ultrasound of the iliac artery with the common femoral artery.</description>
        <time_frame>9 Months</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Limb Revascularization</title>
          <description>Restenosis is defined as a 50% or greater diameter stenosis observed post-procedure through the 9 month timepoint. Restenosis is initially assessed by Duplex Ultrasound of the iliac artery with the common femoral artery.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="3.6" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restenosis Rate (≥ 50% Diameter Stenosis by Duplex Ultrasound Determination)</title>
        <description>Restenosis is defined as a 50% or greater diameter stenosis observed post-procedure through the 9 month timepoint. Restenosis is initially assessed by Duplex Ultrasound of the iliac artery with the common femoral artery.</description>
        <time_frame>9 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Restenosis Rate (≥ 50% Diameter Stenosis by Duplex Ultrasound Determination)</title>
          <description>Restenosis is defined as a 50% or greater diameter stenosis observed post-procedure through the 9 month timepoint. Restenosis is initially assessed by Duplex Ultrasound of the iliac artery with the common femoral artery.</description>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" lower_limit="0.2" upper_limit="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>Death can be classified as one of three categories: cardiac, vascular, or non-cardiovascular. All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established.</description>
        <time_frame>9 Months</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>Death can be classified as one of three categories: cardiac, vascular, or non-cardiovascular. All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" lower_limit="0.2" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Target Limb Loss</title>
        <description>Amputation of the target limb by surgical removal of tissue anywhere from the toe to hip in the ipsilateral limb of the target segment. Amputations are subclassified as: Above the knee, Below the knee, Transmetatarsal, and Toe.</description>
        <time_frame>9 Months</time_frame>
        <population>Intention to Treat Population (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>Scuba Iliac Stent System</title>
            <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Limb Loss</title>
          <description>Amputation of the target limb by surgical removal of tissue anywhere from the toe to hip in the ipsilateral limb of the target segment. Amputations are subclassified as: Above the knee, Below the knee, Transmetatarsal, and Toe.</description>
          <population>Intention to Treat Population (ITT)</population>
          <units>Percentage of Patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From subject index procedure through the 9 month follow-up visit period.</time_frame>
      <desc>In this study, subjects were encouraged to report adverse events (AEs) spontaneously or in response to general, non-directed questioning (e.g., “How has your health been since the last visit?”). Any time during the study, the subject may volunteer information that resembles an adverse event (AE).</desc>
      <group_list>
        <group group_id="E1">
          <title>Scuba Iliac Stent System</title>
          <description>Device: Scuba™ iliac stent
Scuba Iliac Stent System : The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Atrial Fibrilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>In-stent Arterial Restenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Stent Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Thrombus in Device</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Cervical Spinal Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer Recurrent</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Oesophageal Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Rectal Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Arterial Thrombus Limb</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Hypertensive Emergency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Iliac Artery Occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Iliac Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Iliac Artery Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Leriche Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Dissection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Peripheral Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Subclavian Artery Stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter Site Haematoma</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Femoral Artery Stenosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="141"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Dissection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="141"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Medtronic has a legitimate interest in ensuring that a multi-center publication is the first publication to be released regarding the completed Study. The Institution agrees that it will not publish or disclose any results of or information pertaining to the study until a multi-center publication is released. If a publication is not released within one year after completion of the study, the Institution will have the right to publish information pertaining to their activities conducted.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arslan Malik - Senior Clinical Research Manager</name_or_title>
      <organization>Medtronic Aortic and Peripheral Vascular</organization>
      <phone>(707) 541-3256</phone>
      <email>arslan.malik@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

